TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03858920

Intervention type: DEVICE
Intervention: Fibroscan of Liver
Description: A non-invasive diagnostic device used to measure liver scarring

Intervention type: DEVICE
Intervention: Fibroscan of Liver
Description: A non-invasive diagnostic device used to measure liver scarring

Intervention type: PROCEDURE
Intervention: Low-dose non-contrast CT
Description: CT scan as part of routine research care

Intervention type: PROCEDURE
Intervention: Low-dose non-contrast CT
Description: CT scan as part of routine research care
Study: NCT04215952

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantic Feature Analysis Treatment
Description: On each treatment trial, the clinician will show the participant with aphasia a pictured object and ask them to name it. The clinician will then guide the participant in verbally generating semantic features for the target, using a chart that specifies five kinds of features: group, use/action, properties, location, and personal associations. When the participant cannot generate a given feature, cueing or other assistance will be provided. After feature generation, the clinician will ask the participant to name the picture again and provide cueing if needed. The clinician will then review the generated features and ask the participant to name the item once more, with cueing if needed. Finally, the clinician will ask the participant to say a sentence containing the target word and provide cueing if needed. Treatment will then proceed to the next item. Participants will receive approximately 20 hours of treatment on each of three 10-item lists, for a total of 60 hours of treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic Feature Analysis Treatment
Description: On each treatment trial, the clinician will show the participant with aphasia a pictured object and ask them to name it. The clinician will then guide the participant in verbally generating semantic features for the target, using a chart that specifies five kinds of features: group, use/action, properties, location, and personal associations. When the participant cannot generate a given feature, cueing or other assistance will be provided. After feature generation, the clinician will ask the participant to name the picture again and provide cueing if needed. The clinician will then review the generated features and ask the participant to name the item once more, with cueing if needed. Finally, the clinician will ask the participant to say a sentence containing the target word and provide cueing if needed. Treatment will then proceed to the next item. Participants will receive approximately 20 hours of treatment on each of three 10-item lists, for a total of 60 hours of treatment.
Study: NCT03635021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
Study: NCT03829020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir Mesylate
Description: Given PO
Study: NCT02556528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Study: NCT01146886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 135585
Description: Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585
Description: Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
Study: NCT03425331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
Study: NCT03438474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical procedure for endometrial cancer
Description: total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard surgical procedure for endometrial cancer
Description: total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: systematic lymphadenectomy (LNE)
Description: systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels
Study: NCT01360021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: Breath actuated metered dose inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: Actuation counter pressured metered dose inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Actuation counter pressured metered dose inhaler
Study: NCT03972709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galegenimab
Description: Intravitreal (ITV) injections of galegenimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galegenimab
Description: Intravitreal (ITV) injections of galegenimab

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham control

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham control
Study: NCT02714140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PB-HCT +
Description: Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PB-HCT -
Description: Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
Study: NCT02778204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 8 mg/kg oral solution as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 8 mg/kg oral solution as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 8 mg/kg oral solution given twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 8 mg/kg oral solution given twice daily.
Study: NCT04662307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent cardiopulmonary rehabilitation system (ICRS)
Description: Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%\~80% HRR determined in the pretest of cardiopulmonary exercise test.
Study: NCT01985737

Intervention type: OTHER
Intervention: Sample collection

Intervention type: OTHER
Intervention: Sample collection
Study: NCT02422030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor Tab. 40mg
Study: NCT00432926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDGE counseling, no maintenance
Description: Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
Study: NCT02714140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic incentive
Description: Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
Study: NCT00432926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDGE counseling, plus maintenance
Description: Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
Study: NCT02714140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic incentive
Description: Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Economic incentive
Description: Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
Study: NCT03514732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MELATONIN (MELATL07959)
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study: NCT03818113

Intervention type: OTHER
Intervention: cardioplegia with HTK-Bretschneider cardioplegic solution
Description: cardioplegia with HTK-Bretschneider cardioplegic solution

Intervention type: OTHER
Intervention: cardioplegia with St. Thomas cardioplegic solution
Description: cardioplegia with St. Thomas cardioplegic solution
Study: NCT00576719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive panic control treatment without parent involvement
Description: Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive panic control treatment with parent involvement
Description: Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist control
Description: Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
Study: NCT02828579

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
Study: NCT00722228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous or Allogeneic tumor cells
Description: Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
Study: NCT00626002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: 100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
Study: NCT02714140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PB-HCT ++
Description: Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Reminder
Description: Participants will receive an SMS reminder to test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Reminder
Description: Participants will receive an SMS reminder to test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Reminder
Description: Participants will receive an SMS reminder to test.
Study: NCT01054469

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block placement with placebo
Description: 20 ml of normal saline (placebo)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of block with ropivacaine
Description: 20 ml of 0.5% ropivacaine hydrochloride
Study: NCT01243866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive dental treatment
Description: Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Only emergency dental treatment
Description: Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
Study: NCT00891527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
Description: Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated.
Study: NCT02890966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Day1\~Day7:oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Day1\~Day7:oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Day1\~Day7:oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Day1\~Day7:oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Day1\~Day7:oral administration
Study: NCT00789048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radiograph
Description: One radiograph with the patient lying on his contralateral side
Study: NCT00505063

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immunization Schedule patients <7 years.
Description: * Time 0 months: Prevnar 13 #1, Hib #1~* Time 1 months: Pediarix #1~* Time 2 months: Prevnar 13 #2, Hib #2~* Time 3-4 months: Pediarix #2~* Time 4-6 months: Draw post vaccine titers~* Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.
Study: NCT02890966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Day1\~Day7:oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Day1\~Day7:oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Day1\~Day7:oral administration
Study: NCT03121560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopy
Description: Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysterosonography
Description: Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
Study: NCT00350818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 8 mg/m\^2 Subcutaneously Once Daily for 5 Days
Study: NCT01955473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
Study: NCT01721824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The IPS-MA method
Description: During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
Study: NCT02422030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor Tab. 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor Tab. 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor Tab. 40mg
Study: NCT02087826

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Tolerance Test
Description: The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
Study: NCT00505063

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immunization Schedule patients > or = to 7 years and <11 years of age
Description: * Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1~* Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2~* Time 2-3 months: Prevnar 13 #2, Hib #2~* Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immunization Schedule patients > or = to 11 years of age
Description: * Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1~* Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2~* Time 2-3 months: Hib #2, Prevnar 13#2, Menactra~* Time 3-6 months: IPV, Draw post vaccine titers~* Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)
Study: NCT02626091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left-sided colonic resection
Description: During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.~In any case, the resection will be performed according to the surgeon's appreciation.